Blood test may predict how long CAR-T therapy lasts in myeloma patients
NCT ID NCT07342179
First seen Jan 22, 2026 · Last updated May 17, 2026 · Updated 17 times
Summary
This study observes 60 adults with multiple myeloma who are about to receive CAR-T cell therapy. Researchers will measure a specific immune marker (TCF-1) in patients' blood before treatment and track how long the modified CAR-T cells survive afterward. The goal is to find clues that predict which patients will have a lasting response, without giving any new treatment or changing standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu de Poitiers
RECRUITINGPoitiers, 86000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.